A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation.

BACKGROUND: Irritable bowel syndrome (IBS) and chronic constipation (CC) are common functional gastrointestinal disorders affecting 14% and 20% of the U.S. population, respectively. Reviews of the evidence on the burden of illness associated with IBS and CC have not been comprehensive in scope and have not provided an assessment of the distribution of health care costs across categories of resource use. OBJECTIVES: To (a) identify studies from any geographic region or country perspective that measure the economic burden of the disease; (b) analyze the direct (medical, drug, and other components) and indirect costs of illness; and (c) assess published evidence of the humanistic burden as measured by quality of life (QOL). METHODS: An electronic literature search was conducted using journal databases, including MEDLINE, The Cochrane Library, EconLit, CINAHL, and Digestive Disease Week meeting abstracts. Specific search terms used were "irritable bowel syndrome" and "chronic constipation." In databases that accommodated Boolean searches, terms related to economic and quality of life outcomes were incorporated. Studies were included if they evaluated patients with an IBS or CC diagnosis and quantitatively measured the economic or humanistic burden of disease. Results were descriptively analyzed. RESULTS: The search identified a total of 882 unique publications. Thirty-five articles and abstracts met the inclusion criteria. Studies included 1,706 IBS-C, 2,264 IBS-D, 2,892 IBS-A, 15,830 IBS unclassified, and 1,278 CC patients. Nineteen of 35 studies assessed cost-of-illness endpoints, and from the U.S. perspective, the direct cost per-patient for IBS ranged from $1,562 to $7,547 per year, while direct costs of CC ranged from $1,912 to $7,522 per year. From the U.S. perspective, the indirect costs of IBS ranged from $791 to $7,737 per year, and no study assessed the indirect costs of CC. For IBS, data on the distribution of costs attributable to categories of resource use varied widely, particularly outpatient costs (12.7% to > 50% of total costs), inpatient costs (6.2% to 40.8%), and pharmacy or drug costs (5.9% to 46.6%). Comparable data on CC were not identified. Nineteen studies of IBS patients measured the humanistic burden of disease; 14 studies utilized SF-36; and within-study domain scores were significantly lower in IBS patients compared with non-IBS controls. Only 1 study of CC patients reported humanistic burden of disease. CONCLUSIONS: The studies identified in the systematic review varied in the method used to identify patients with IBS and CC. Results were not typically reported by IBS subtype. We observed a large variation in attributable direct and indirect costs and drivers of these costs. Future research should refine burden of illness estimates to subtypes so that estimates associated with IBS-C and CC are differentiated.

Impact of bipolar disorder on the family: utilization and cost of health care resources.

OBJECTIVE: Our retrospective analysis compared costs and patterns of health care utilization by families that included a member with bipolar disorder ("bipolar families") and by families without serious psychiatric disease ("control families"). METHODS: We used the MarketScan Commercial Claims and Encounters Database covering January 1998 through December 2002. International Classification of Diseases (ICD-9-CM) codes were used to identify individuals with bipolar disorder and link them to their family members. Bipolar families were matched in a ratio of 1:3 to families without a serious mental illness. We calculated and statistically compared the mean annual use of resources and health care costs for each group, including the individual with bipolar disorder. We used a multivariate model to test the effect of demographic and health care variables on the impact of total health care expenditures. RESULTS: Families with a member with bipolar disorder (n = 43,448), compared with matched families (n = 122,769), made significantly more outpatient physician visits (24 vs. eight; P < 0.001), more inpatient hospital stays (1 vs. 0.3; P < 0.001), and more prescription medications (24 vs. 7.8; P < 0.001). Total annual health care costs were more than three-fold higher for bipolar families ($4,664), compared with matched families ($1,376) (P < 0.001). The multivariate model controlled for family size and comorbidities, indicating significantly higher total health care costs for families with one or more persons with bipolar disorder than for matched families without serious mental illness. CONCLUSION: These results indicate that bipolar disorder has a significant financial impact on families in addition to the individual with the diagnosis.

Association between common asthma therapies and recurrent asthma exacerbations in children enrolled in a state Medicaid plan.

PURPOSE: To evaluate the effectiveness of budesonide inhalation suspension relative to other common asthma therapies in a high-risk population, a study was conducted to compare the risk of having a repeat asthma-related hospitalization or emergency department (ED) visit in a Medicaid population of children; the relationship between asthma medication adherence level and repeat asthma hospitalizations or ED visits was also evaluated. METHODS: Children eight years of age or younger, with a hospitalization or ED visit for asthma between January 1999 and June 2001 (index event), were identified in a Florida Medicaid database. Claims data for each child were examined 12 months before and after the index event. Cox proportional hazards regression was used to model the risk of subsequent asthma exacerbation according to the asthma medication received during the first 30 days after the index event. Logistic regression was used to model the relationship between medication adherence as measured by the medication possession ratio (MPR) and the likelihood of a subsequent asthma exacerbation. RESULTS: There were 10,976 children in the study. Patients who had a claim for budesonide inhalation suspension had a lower risk of a subsequent hospitalization or ED visit (hazard ratio, 0.55; 95% confidence interval, 0.41-0.76; p < 0.001) than patients who did not have budesonide inhalation suspension claims. Other controller medications were not associated with a reduction in the risk of subsequent asthma exacerbations. Adherence to medication was poor (a median MPR of 0.08 for budesonide inhalation suspension and a median MPR of 0.16 for any asthma controller medication). The odds of a repeat hospitalization or ED visit were significantly lower for children who were adherent to their asthma controller medication. CONCLUSION: Children with asthma and insured by Medicaid were at a high risk of repeat exacerbations leading to increased hospitalizations and ED visits. Treatment with budesonide inhalation suspension in the first 30 days after a hospitalization or ED visit for asthma was associated with a significant reduction in the risk of repeat asthma-related hospitalizations or ED visits during the following year. Children who were adherent to their asthma controller medication had significantly lower odds of having a subsequent asthma exacerbation.

Dyslipidemia treatment among patients with coronary artery disease in a managed care organization.

PURPOSE: The statin-prescribing patterns in a large managed care organization and the effectiveness of statin prescriptions in lowering low-density-lipoprotein (LDL) cholesterol levels in patients with coronary artery disease (CAD) or risk-equivalent patients were examined. METHODS: A retrospective review of the records in an integrated medical, pharmacy, and laboratory database was performed. The qualifying period for the study began January 1, 1999, and ended December 31, 2000; the reporting period extended from January 1, 2001, to December 31, 2001. Patients included in this study had a medical claim indicative of a diagnosis of CAD or risk equivalence during the qualifying 18-month period. The data were examined to determine percentages of patients who were tested for circulating LDL cholesterol levels, were prescribed statins, and achieved the LDL cholesterol goal recommended by the National Cholesterol Expert Panel. Physician prescribing patterns were also examined. RESULTS: During the 12-month analysis period of the study, 24% of patients were tested for circulating LDL cholesterol levels, and 39.8% received at least one statin. Of patients whose LDL cholesterol values were documented and who received statins, 44.5% achieved goal LDL cholesterol levels. Of patients who were tested and did not receive statins, 29.8% achieved the LDL cholesterol goal. Cardiologists prescribed statins to CAD patients at a higher rate than other specialists or primary care providers. CONCLUSION: Patients with a diagnosis of CAD or risk equivalence, who would benefit from treatment to reduce circulating LDL cholesterol levels, were significantly undertreated.

Compliance with pharmacologic therapy for osteoporosis.

There is little information available concerning compliance with pharmacologic therapy for osteoporosis in the usual care setting. We evaluated 176 consecutive, previously untreated women whose physicians initiated treatment for osteoporosis following a bone mineral density (BMD) test obtained as part of routine medical practice. All patients were contacted >/=1 year after the initial BMD test and offered a follow-up BMD. Compliance with therapy was defined as the percent of time that a patient filled a prescription for osteoporosis treatment. Ninety-three (53%) patients received estrogen (ERT), 93 (53%) bisphosphonates, 8 (5%) calcitonin, and 17 (10%) received more than one therapy. Ninety-one of the 176 (52%) agreed to a follow-up BMD at a mean of 590 days after the first study (participants); 85 declined a follow-up BMD (refusers). Participants and refusers were similar for age, treatment patterns, and compliance with therapy. For all patients, compliance for those given bisphosphonate was similar to those given ERT (70.7% (95% CI 63.5-77.9%) versus 69.2% (95% CI 61.7-76.8%). For participants, the change in spine BMD was similar for those treated with bisphosphonate [mean increase 3.53 (+/-2.64)%/year (mean+/-SD)] and those treated with ERT [mean increase 3.00 (+/-2.75)%/year]. For those participants whose compliance with therapy was >/=66%, the mean increase in spine bone density was 3.80 (+/-2.59)%/year compared to 2.11 (+/-2.64)%/year ( p<0.005) for those whose compliance was <66%. Compliance with ERT and bisphosphonate therapy initiated in routine practice after a BMD was similar over a mean of 590 days. Compliance less than 66% with drug treatment results in suboptimal improvement in bone density.

Challenges of estimating health service utilization for osteoarthritis patients on a population level.

OBJECTIVE: To examine how estimates of osteoarthritis (OA) related health service utilization and medical care charges vary based on how the population of patients is defined, we compared a large cohort of patients identified through an administrative OA diagnosis relative to a subgroup of patients in whom this diagnosis had been validated through medical record review. METHODS: We identified all members (> or = 18 years of age) of a Massachusetts group model health maintenance organization (HMO) with documentation of at least one health care encounter associated with an OA diagnosis during the period 1994-96 (n = 10,740). From this population we randomly selected 700 subjects. Trained nurse reviewers abstracted relevant clinical, laboratory, and radiologic data from their medical records. Physician reviewers evaluated the abstracted information and rated the evidence for the presence of OA according to 3 levels (definite, possible, and unlikely). All persons rated by the physician reviewers as having definite OA were included in the validated subgroup (n = 442). Health service utilization and medical care charges were assessed in all persons with an administrative OA diagnosis who were not randomly sampled (n = 10,040) and the validated subgroup (n = 442) across the following domains: (1) ambulatory encounters associated with an OA diagnosis, (2) relevant radiographic studies, (3) relevant surgical procedures, and (4) relevant medication use. RESULTS: Those in the validated subgroup had higher rates of ambulatory OA associated health care encounters, radiographic studies, surgical procedures, and analgesic and/or antiinflammatory medication dispensings. Patients in the validated subgroup were significantly more likely to be in the highest quartile for total one year charges for the care of OA. CONCLUSION: Estimates of health service utilization are substantially higher for populations of patients in whom a diagnosis of OA has been validated through medical record review, as compared with unvalidated populations identified solely through diagnoses contained in administrative records. Thus using health service utilization estimates based on an unvalidated sample may lead to an inaccurate estimate when extrapolated to the overall population of patients with OA.